Chemotherapy was not associated with increased risks of SARS-CoV-2 infection or COVID-19-related death in patients with breast cancer in a single-center study. The study results were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting by Nibash Budhathoki, MBBS, of the NYU Long Island School of Medicine in Mineola, New York. Dr. […]
Pafolacianine sodium injection could be a real-time adjunct to current surgical practice for ovarian cancer, allowing for more lesions to be removed at the time of surgery, according to a study presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. According to a press release2 from the manufacturer of pafolacianine sodium, many ovarian […]
Therapeutic Options for Patients With High-Risk, HER2-Positive Early Breast Cancer The researchers found that adding 1 year of adjuvant trastuzumab significantly improved disease-free and overall survival and that the risk: benefit ratio favored the nonanthracycline TCH regimen over AC-T plus trastuzumab. Efficacy was similar, and there were fewer acute toxic effects and lower risks of […]
Researchers evaluated the clinical utility of genetic testing with MammaPrint 70-gene signature to determine how well this assay works in comparison with clinical assessment to determine the need for chemotherapy in women with breast cancer involving 0 to 3 lymph nodes. The phase 3 MINDACT findings, which included the survival outcomes of patients with an […]
Study Reports Improved Outcomes With Olaparib Maintenance in Ovarian Cancer Maintenance therapy with olaparib was found to result in a clinically meaningful, but not statistically significant, improvement in overall survival compared with placebo among women with platinum-sensitive, BRCA 1/2-mutated, relapsed ovarian cancer, according to the results of a study published in The Lancet Oncology. […]
Cancer Therapy Advisor (4/19, Blevins Primeau) reports, “Maintenance therapy with olaparib was found to result in a clinically meaningful, but not statistically significant, improvement in overall survival compared with placebo among women with platinum-sensitive, BRCA 1/2-mutated, relapsed ovarian cancer, according to” a study. The findings were published in The Lancet Oncology. […]
Healio (4/13, Lawrence) reports that “a personalized genomic vaccine administered after standard-of-care adjuvant therapy appeared safe and induced immunogenicity among patients with different cancers at a high risk for recurrence, according to results of a phase 1 trial.” The research, “presented at the virtual American Association for Cancer Research Annual Meeting, also showed feasibility of developing the […]
Cancer Network (4/5, Sternberg) reports, “A final analysis of the phase 3 SOLO2 trial (NCT01874353) examining olaparib (Lynarza) tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and BRCA1/2 mutations following 2 or more prior platinum regimens showed a trend toward overall survival (OS) superiority versus placebo maintenance.” The results were published in Lancet Oncology. […]
Cancer Network (3/31, Seymour) reports, “In patients with an abnormal CA-125 level at the beginning of frontline maintenance therapy, surveillance of CA-125 alone may be used to detect disease progression of advanced ovarian cancer being treated with olaparib (Lynparza) and bevacizumab (Avastin).” The “results were taken from an analysis of the phase 3 PAOLA-1 trial (NCT02477644) and […]
Magnetic resonance imaging (MRI) was found to provide the most concordant tumor size assessment among breast imaging techniques, although significant overestimation exists, according to research presented at the 17th St. Gallen International Breast Cancer Conference 2021.F.C. Pop, from the Jules Bordet Institute, Université Libre de Bruxelles, in Brussels, Belgium, and colleagues included 752 patients (mean […]